Increased serum levels of eotaxin in patients with inflammatory bowel disease

Citation
W. Chen et al., Increased serum levels of eotaxin in patients with inflammatory bowel disease, SC J GASTR, 36(5), 2001, pp. 515-520
Citations number
41
Categorie Soggetti
Gastroenerology and Hepatology","da verificare
Journal title
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
ISSN journal
00365521 → ACNP
Volume
36
Issue
5
Year of publication
2001
Pages
515 - 520
Database
ISI
SICI code
0036-5521(200105)36:5<515:ISLOEI>2.0.ZU;2-Y
Abstract
Background: The CC-chemokines eotaxin and eotaxin-2. produced by epithelial and phagocytic cells, are potent and selective chemoattractants for eosino phils and basophils. The eosinophil is a potent inflammatory cell thought t o play an important role in the pathogenesis of inflammatory bowel disease (IBD). In this study we investigated the serum concentrations of eotaxin an d eotaxin-2 in patients with Crohn disease and ulcerative colitis. Methods: Thirty-one patients with Crohn disease. 35 patients with ulcerative coliti s and 41 control patients were studied. Eotaxin and eotaxin-2 serum levels were measured with solid phase sandwich enzyme-linked immunosorbent assays. Results: Significantly increased serum eotaxin levels were observed in bot h patients with Crohn disease (289.4 +/- 591.5 pg/ml) and ulcerative coliti s (207.0 +/- 243.3 pg/ml) when compared with controls (138.0 +/- 107.8 pg/m l) (P < 0.01). Moreover, patients with active Crohn disease and ulcerative colitis showed significantly higher serum eotaxin levels than patients with quiescent disease (434.0 +/- 776.8 pg/ml versus 113.8 +/- 65.4 pg/ml in Cr ohn disease and 295.7 +/- 337.1 versus 121.2 +/- 91.9 pg/ml in ulcerative c olitis. P < 0.05). In contrast, there was no significant difference in eota xin-2 serum levels among patients with Crohn disease (863.5 +/- 448.2 pg/ml ), ulcerative colitis (1028.3 +/- 431.4 pg/ml) and controls (981.4 +/- 539. 4 pg/ml). Conclusions: Eotaxin is significantly increased in serum of patie nts with active Crohn disease and ulcerative colitis, suggesting that this cytokine may play a role in the pathogenesis of IBD.